Search Results
Viewing: 41-50 of 55 | All
Article
Muscular Dystrophy Research
Dr. Jerry Mendell and his team have discovered that gene therapy can treat the underlying cause of muscular dystrophy - something that other drugs and medications can't currently do.
Condition
Neuromuscular Disorders
Patients benefit from coordinated care from specialists, all with expertise in pediatric neuromuscular disorders.
Article
MCM-RAG Members
The Molecular and Cellular Medicine-Research Affinity Group is made up of a steering committee and members from both Nationwide Children's Hospital and The Ohio State University. Learn more about its members.
News
Nationwide Childrens Hospital Researchers Receive NIH Grant for the Move Toward Clinical Trials Targeting the Lysosomal Storage Disease MPSIIIB
Investigators at Nationwide Children’s have received a grant from the National Institutes of Health (NIH) to help move a therapy for MPS IIIB that has been shown effective in mice toward clinical trials in humans.
Article
April 2014
Dr. Brian Kaspar discusses a new method for studying ALS, with potential to test therapeutics in individual patients.
Article
Research Faculty Careers
The Abigail Wexner Research Institute (AWRI) at Nationwide Children’s is ranked among the top 10 freestanding children’s hospitals based on NIH funding. On a continuing trajectory of rapid growth, AWRI is looking for new faculty to drive the next generation of discovery at Nationwide Children's.
News
Sarepta Therapeutics Enters Into License Agreement with Nationwide Childrens Hospital for Galgt2 Gene Therapy Program
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered a license agreement with Nationwide Children’s Hospital, for their Galgt2 gene therapy program developed by researcher Paul Martin, PhD.
Article
Endowed Chairs
Endowed chairs at Nationwide Children's Hospital represent the most prestigious and significant recognition of a scientist's or clinician's work.
News
Family Foundations Fund Critical Study Necessary For Clinical Trials And Enter Into Agreement With Nationwide Childrens Hospital To Ensure Data Access For Lysosomal Storage Disease MPS III
Nearly 50 years to the day since Dr. Sylvester Sanfilippo first characterized the disease Mucopolysaccharidosis (MPS) III in a presentation to the American Pediatric Society, three parent-run foundations have awarded investigators at Nationwide Children’s Hospital in Columbus, OH with a
Article
Interprofessional Education and Grand Rounds Update
- Upcoming Conferences
- Pediatric Grand Rounds
- Annual MOC Deadlines
- Lounge and Learn